

Date: March 17, 2026

To,
Sr. General Manager
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

BSE Scrip Code: 544319

To,
Sr. General Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

NSE Symbol: SENORES

Sub.: Changes in the Senior Management Personnel (“SMP”) of the Company

Dear Sir/Madam,

Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015, as amended from time to time, we hereby inform you that on the basis of the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company, through the circular resolution, passed today i.e. Tuesday, March 17, 2026 have approved the appointment and categorization of Mr. Jatin Gajjar, Chief Technology Officer as Senior Management Personnel (“SMP”) of the Company.

Further, we would like to inform that Mr. Manohar Lalge, President –Research and Development has tendered his resignation with effect from the close of the business hours on March 17, 2026. Accordingly, upon resignation he shall cease to be the SMP of the Company.

Details with respect to appointment and resignation of the aforesaid SMPs of the Company as required under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015 read with SEBI master circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 is enclosed herewith as **Annexure-I** and a copy of letter of resignation is enclosed herewith as **Annexure-II**.

This intimation is also being uploaded on the Company’s website at www.senorespharma.com.

You are requested to take the same on record.

Thanking you.

For Senores Pharmaceuticals Limited

Vinay Kumar Mishra
Company Secretary and Compliance Officer
ICSI Membership No.: F11464

Enclosures: As above

Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com

W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263

Details as required under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026:

| Sr.No. | Particulars | Details | |
|--------|--|--|---|
| 1. | Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise | Mr. Jatin Gajjar Chief Technology Officer, categorized as SMP of the Company. | Cessation of Mr. Manohar Lalge, President – Research and Development and SMP of the Company, pursuant to his resignation. |
| 2. | Date of appointment/re-appointment/cessation (as applicable) and term of appointment | Effective from March 17, 2026 Terms and conditions as mentioned in the letter of appointment. | Effective from closure of the business hours of March 17, 2026. |
| 3. | Brief Profile (in case of appointment) | <p>Mr. Jatin Gajjar serves as the Chief Technology Officer of Senores Pharmaceuticals Limited, bringing over three decades of leadership experience in pharmaceutical technology, manufacturing operations and product development.</p> <p>His expertise is in complex formulations, regulatory compliance & process optimization. He has played a pivotal role in advancing complex generics, injectable formulations and novel drug delivery technologies while enabling regulatory approvals and commercialization across key markets. At Senores, he provides strategic leadership, across R&D, manufacturing and RA, aligning technology with our business goals, further improving efficiency and embedding a culture of innovation and scientific excellence.</p> <p>Previously, Mr. Gajjar served as President at QuoSolve</p> | Not Applicable |

Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com

W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263

| | | | |
|----|--|--|----------------|
| | | Pharmaceutical Consultants and held leadership roles at global pharma organizations including Amneal Pharmaceuticals, Sun Pharmaceutical Industries, Alembic, Zydus Cadila, Torrent Pharma and Aventis Pharma. He holds both Bachelor's and Master's degrees in Pharmacy from L.M. College of Pharmacy, Gujarat University, along with a diploma in Marketing and Sales Management from RPICM, Bharatiya Vidya Bhavan. | |
| 4. | Disclosure of relationships between directors (in case of appointment of a director) | Not Applicable | Not Applicable |

Committed to
Global Wellness!



Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com

W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263

Resignation Letter

19/01/2026

To,
Chetan Shah
Director-Operation
Senores Pharma Ltd. Ahmedabad

Dear Sir,


Please accept this letter as my formal notice of resignation from Senores Pharma ltd. effective 19/01/2026 The associations I've made during my employment here will truly be memorable.

I hope a one-month notice is sufficient for you to find a replacement for me. If I can help to train my replacement or tie up any loose ends, please let me know.
Thank you very much for the opportunity to work here.

Thank you,


19/01/2026
Manohar Lalge
President R&D

Your resignation is hereby accepted and you will be relieved from your duties from 17th March 2026. after working hours.


H.S. Chabani
Head-HR